The Vanguard Group, Inc. recently announced the acquisition of new stake in Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX). The institutional investor has increased its shareholding in the Healthcare company by 2.08% to 14.9 million shares with purchase of 0.3 million shares. This fresh investment now brings its stake to 7.28% valued currently at $87.61 million. In addition, BlackRock Fund Advisors raised its holdings by 0.7 million to 14.27 million shares. And Braidwell LP has lifted its position by 92.09% or 2.57 million shares – to 5.36 million shares.
Currently, there are 204.81M common shares owned by the public and among those 199.14M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 30 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 24 of these insider trades were purchases, accounting for 332,607 shares. Insider sales of the common stock occurred on 6 occasions, with total insider shares sold totaling 158,866 shares.
The top 3 mutual fund holders in Biocryst Pharmaceuticals Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 7.1 million shares of the company’s stock, all valued at over $41.75 million. The company bought an additional 33090.0 shares recently to bring their total holdings to about 3.47% of the shares outstanding. Vanguard Total Stock Market ETF bought 58552.0 shares to see its total holdings expand to 5.93 million shares valued at over $34.86 million and representing 2.90% of the shares outstanding. iShares Russell 2000 ETF bought 2262.0 shares to bring its total holdings to over 4.6 million shares at a value of $27.04 million. iShares Russell 2000 ETF now owns shares totaling to 2.25% of the shares outstanding.
However, the script later moved the day high at 6.27, down -0.33%. The company’s stock has a 5-day price change of 1.68% and -14.91% over the past three months. BCRX shares are trading -47.30% year to date (YTD), with the 12-month market performance down to -44.70% lower. It has a 12-month low price of $4.82 and touched a high of $12.07 over the same period. BCRX has an average intraday trading volume of 3.75 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.14%, 6.17%, and -15.64% respectively.
Institutional ownership of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares accounts for 85.75% of the company’s 204.81M shares outstanding. Mutual fund holders own 32.72%, while other institutional holders and individual stakeholders account for 53.07% and 11.66% respectively.
It has a market capitalization of $1.24B and a beta (3y monthly) value of 1.90. The earnings-per-share (ttm) stands at -$1.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.98% over the week and 7.16% over the month.
Analysts forecast that Biocryst Pharmaceuticals Inc. (BCRX) will achieve an EPS of -$0.24 for the current quarter, -$0.23 for the next quarter and -$0.69 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.38 while analysts give the company a high EPS estimate of -$0.14. Comparatively, EPS for the current quarter was -$0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 21.35%, and 31.25% over the next financial year. EPS should grow at an annualized rate of 44.80% over the next five years, compared to -11.25% over the past 5-year period.
Looking at the support for the BCRX, a number of firms have released research notes about the stock. JP Morgan stated their Overweight rating for the stock in a research note on November 20, 2023, with the firm’s price target at $10.
